ArticleRespiratory medicine case reports2024
A case report of high-grade fetal lung adenocarcinoma with KRAS mutation.
Article in Respiratory medicine case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fetal lung adenocarcinoma (FLAC) is a rare malignant tumor with a relatively good prognosis, and the probability of mutation with KRAS is very low. We report a middle-aged female patient with FLAC with KRAS mutation. The primary lesion was implanted with radioactive iodine 125 particles, and the lesion was smaller than before. However, the metastatic lesions progressed rapidly. After chemotherapy with pemetrexed disodium and cisplatin combined with bevacizumab to prevent angiogenesis, the primary lesions continued to shrink, and the metastatic lesions were significantly smaller than before. The patient has been followed up for 5 months and is generally in good condition. We report a case of H-FLAC with KRAS mutation, and its development and prognosis seem to be significantly abnormal from that of ordinary H-FLAC. It also provides a possible effective treatment for unresectable H-FLAC, but further research is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.